Sarcoidosis after interferon therapy for chronic active hepatitis C.
Sarcoidosis is characterized by multisystemic granulomatous lesions of unknown etiology. A 62-year-old woman developed sarcoidosis after treatment with alpha-2a interferon (IFN) for 24 weeks (total dose: 522 million units) for chronic hepatitis C. She developed complete atrioventricular block and multiple noncaseating granulomatous lesions in the lung. IFN therapy, which may disturb cellular immune activation in some patients, may have contributed to the onset and progression of sarcoidosis.
Teragawa
H
H
Department of Internal Medicine, Onomichi General Hospital.
Hondo
T
T
Takahashi
K
K
Watanabe
H
H
Ohe
H
H
Hattori
N
N
Watanabe
Y
Y
Amano
H
H
Hino
F
F
Ohbayashi
M
M
Urushihara
T
T
Yonehara
S
S
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006327:Heart Block / Q000139:chemically induced* / Q000503:physiopathology; D006526:Hepatitis C / Q000188:drug therapy*; D006521:Hepatitis, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011994:Recombinant Proteins; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D014057:Tomography, X-Ray Computed
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins